Medicare Advantage Prior Auth Denials Are Reversible

A new study examining Medicare Advantage prior authorization denials and appeal outcomes is putting numbers behind what many billing teams already know by experience: MA plans are denying prior auth requests at concerning rates, but appeals still have teeth. For HME and DME billers especially, understanding your appeal win rate on MA denials isn't academic—it's the difference between days in AR climbing to 60+ or staying manageable.

What's Actually Happening

The study examined prior authorization denial patterns across Medicare Advantage plans, focusing on both initial denial rates and the success rates when providers appeal. While specific percentages vary by plan and region, the research underscores a consistent finding: MA plans are denying a meaningful volume of prior auth requests that would likely be approved under traditional Medicare.

HME and DME suppliers are among the hardest hit. Prior authorization requirements for items like power mobility devices, oxygen equipment, and wound care supplies have become standard gatekeeping tools for MA insurers—and denials on technical grounds (missing documentation, outdated medical records, coding mismatches) are common. What the data shows is encouraging: providers who appeal denials win a significant percentage of cases, suggesting many initial denials are defensible rather than final.

Why It Matters for Billing Teams

If your MA denial rate on prior auth requests is high, the study signals that surrendering on the first denial is leaving money on the table. This matters operationally because:

• Appeal success rates justify staffing. If 40-50% of MA prior auth denials can be overturned on appeal (and studies suggest the range is significant), your back-office has a clear ROI on dedicated appeal staff rather than write-offs.
• Denial root causes are fixable. Most prior auth denials aren't coverage policy rejections—they're administrative: missing clinical data, outdated prescriptions, mismatched ICD-10 codes. That's process work, not payor intransigence.
• MA plans have contractual obligations. Prior auth timelines and denial ratios may be spelled out in your participation agreements. If a plan's denial rate on clinically appropriate requests is outlier-high, that's a payor relations conversation waiting to happen.

What To Do About It

• Audit your MA prior auth denial reasons. Pull the last 30 days of MA denials. Bucket them: clinical review denials vs. administrative/documentation denials. The latter are your quick wins.
• Build an appeal protocol for MA plans specifically. Don't treat MA prior auth denials the same as commercial. MA has different appeals workflows and timelines. Document the clinical necessity narrative upfront, bundle supporting records, and file within the plan's window.
• Track appeal win rates by plan. If UnitedHealthcare MA denials reverse at 45% on appeal but Humana MA denials reverse at 20%, that's actionable intel for your payor relations team and future contracting.
• Front-load prior auth documentation. The study implies many denials stem from incomplete clinical records at submission. Before you submit a prior auth request to an MA plan, run an internal checklist: recent exam notes, current prescriptions, ICD-10 codes tied to medical necessity.
• Escalate serial denials to plan management. If a specific MA plan is denying >40% of prior auth requests on clinically routine items (e.g., standard power wheelchair configurations), document the pattern and loop in your payor rep. Contractual discussions often follow.

The Bigger Picture

MA plans have financial incentives to deny—every prior auth rejection is a short-term cost avoidance. But the sustainability of those denials in appeals suggests they're often indefensible, or at least not worth litigating beyond a first appeal. That's a feature of the MA market: plans are willing to say "no" initially because they know a chunk of denials will stick, but they're not willing to fight provider appeals indefinitely. For billers, that means your appeal function isn't a grudge match against payors—it's a predictable revenue recovery operation that, executed well, moves the needle on overall AR aging and payor profitability.

The real question isn't whether MA plans are denying aggressively—they are. It's whether your billing operation is equipped to appeal systematically and win. The data says you should be.

Published by RevCycleAI Research · August 17, 2026